After lung cancer subtyping is complete, non LUSC are evaluated for targetable driver genomic alterations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, c-Ros oncogene 1 (ROS1) rearrangements, and BRAF V600E mutation. Here, EGFR is linked to lung cancer.